©The Author(s) 2015. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Gastroenterol. Jul 14, 2015; 21(26): 8156-8162
Published online Jul 14, 2015. doi: 10.3748/wjg.v21.i26.8156
Published online Jul 14, 2015. doi: 10.3748/wjg.v21.i26.8156
Stereotactic body radiotherapy using CyberKnife for locally advanced unresectable and metastatic pancreatic cancer
Ting-Shi Su, Ping Liang, Huan-Zhen Lu, Jian-Ning Liang, Jian-Min Liu, Ying Zhou, Ying-Chuan Gao, Min-Yang Tang, Department of Radiation Oncology, Rui Kang Hospital, Guangxi Traditional Chinese Medical University, Nanning 530001, Guangxi Zhuang Autonomous Region, China
Author contributions: Su TS and Liang P performed the majority of experiments and designed the study; Su TS wrote the manuscript; Lu HZ and Liang JN collected all the clinical materials; Liu JM, Zhou Y, Gao YC and Tang MY provided vital reagents and analytical tools and were also involved in revising the manuscript.
Institutional review board statement: The study was reviewed and approved by the Medical Ethics Committee of Rui Kang Hospital.
Informed consent statement: All study participants, or their legal guardian, provided informed written consent prior to study enrollment.
Conflict-of-interest statement: The authors have no conflict of interest to disclose.
Data sharing statement: Statistical code and dataset available from the corresponding author at sutingshi@163.com.
Correspondence to: Dr. Ting-Shi Su, Department of Radiation Oncology, Rui Kang Hospital, Guangxi Traditional Chinese Medical University, No. 10 Huadong Road, Nanning 530001, Guangxi Zhuang Autonomous Region, China. sutingshi@163.com
Telephone: +86-771-2250120 Fax: +86-771-2250120
Received: January 7, 2015
Peer-review started: January 8, 2015
First decision: January 22, 2015
Revised: February 3, 2015
Accepted: March 18, 2015
Article in press: March 19, 2015
Published online: July 14, 2015
Processing time: 187 Days and 13.7 Hours
Peer-review started: January 8, 2015
First decision: January 22, 2015
Revised: February 3, 2015
Accepted: March 18, 2015
Article in press: March 19, 2015
Published online: July 14, 2015
Processing time: 187 Days and 13.7 Hours
Core Tip
Core tip: Locally advanced unresectable and metastatic pancreatic cancer is the most common presentation of pancreatic cancer. The available therapeutic option is chemotherapy or chemoradiotherapy. The low-dose radiation of conventional radiotherapy has unsatisfactory results for survival and local control, at a cost of increased hematologic toxicity. Doses > 54 Gy may be considered if clinically appropriate. Stereotactic body radiation therapy has become an important research topic to provide a higher biologically effective dose. We evaluated the efficacy and toxicity of stereotactic body radiation therapy using the CyberKnife system for patients with locally advanced unresectable and metastatic pancreatic cancer.